血液中のTMB(bTMB)が非小細胞肺がんへの抗PD-L1抗体アテゾリズマブ治療のバイオマーカーに【ESMO】

Blood-based Tumour Mutational Burden Assay Predicts Clinical Benefit in NSCLC Patients Treated with Atezolizumab

 Results based on retrospective analysis of two large randomised trials

 

コメント

Leave a comment

Your email address will not be published.


*